Dr. Reddy's Laboratories Limited's API facility at Srikakulam completes USFDA inspection successfully

The United States Food & Drug Administration (USFDA) today completed a Pre-Approval Inspection (PAI) and a routine GMP inspection at Dr. Reddy's Laboratories Limited's API manufacturing facility in Srikakulam, Andhra Pradesh, India (CTO-6). The inspection was conducted from 10th July, 2023 to 19th July, 2023. The inspection closed with zero observations and a classification of No Action Indicated (NAI).

Shares of Dr. Reddy's Laboratories Limited was last trading in BSE at Rs. 5221.60 as compared to the previous close of Rs. 5190.80. The total number of shares traded during the day was 10515 in over 1284 trades.

The stock hit an intraday high of Rs. 5269.25 and intraday low of 5144.80. The net turnover during the day was Rs. 54716179.00.

Source : Equity Bulls

Keywords

DrReddysLaboratories INE089A01023 RDY Pharmaceuticals USFDA PAI GMPInspection APIManufacturingFacility Srikakulam